Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Protagonist Therapeutics (Nasdaq: PTGX) will be presenting at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 3:00 p.m. EST. The presentation by CEO Dinesh V. Patel will be available via live and archived webcast on their official website.

The company is advancing multiple clinical trials, including the REVIVE Phase 2 trial for rusfertide, aimed at treating polycythemia vera, and IDEAL Phase 2 study for PN-943 in ulcerative colitis.

NEWARK, Calif., Feb. 10, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17th at 3:00 p.m. EST.

A live and archived webcast of the event will be available in the Investors section of the Protagonist Therapeutics website at https://investors.protagonist-inc.com/.

About Protagonist

Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based new chemical entities in different stages of clinical development, all derived from the Company's proprietary technology platform.

Protagonist's pipeline includes rusfertide, an investigational, injectable hepcidin mimetic currently in the REVIVE Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), the PACIFIC Phase 2 study in PV subjects with high hematocrit levels, and a recently completed Phase 2a study for hereditary hemochromatosis. The Company is actively initiating PERSIST, a single, global Phase 3 randomized, placebo-controlled trial evaluating the efficacy and safety of a once weekly, subcutaneously self-administered dose of rusfertide.

The Company is also evaluating an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide (PN-943), currently in the IDEAL Phase 2 study in adults with moderate to severe active ulcerative colitis (UC). The Company is targeting ulcerative colitis as the initial indication.

The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of oral peptide IL-23 receptor antagonist PN-235 (JNJ-77242113), a second-generation oral interleukin-23 receptor antagonist candidate. Under the collaboration with Janssen, PN-235 is expected to advance into Phase 2b studies in psoriasis and at least one new Phase 2 clinical study in inflammatory bowel disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-11th-annual-svb-leerink-global-healthcare-conference-301479454.html

SOURCE Protagonist Therapeutics, Inc.

FAQ

What is the date and time of Protagonist Therapeutics' presentation at the SVB Leerink Conference?

Protagonist Therapeutics will present on February 17, 2022, at 3:00 p.m. EST.

Where can I watch the Protagonist Therapeutics presentation?

The presentation can be watched live and archived on the Protagonist Therapeutics website under the Investors section.

What clinical trials is Protagonist Therapeutics currently conducting?

Protagonist is conducting multiple trials, including REVIVE Phase 2 for rusfertide and IDEAL Phase 2 for PN-943.

What is rusfertide being tested for?

Rusfertide is being tested in the REVIVE Phase 2 trial for treating polycythemia vera.

What is the focus of the IDEAL Phase 2 study by Protagonist Therapeutics?

The IDEAL Phase 2 study focuses on an orally delivered peptide PN-943 for moderate to severe active ulcerative colitis.